SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
Rhea-AI Summary
SI-BONE (Nasdaq:SIBN) will participate in the 2026 Truist Securities MedTech Conference in Boston, MA. Management will host a fireside chat on June 16, 2026 at 5:40 a.m. PT / 8:40 a.m. ET.
A live audio webcast and 90-day replay will be available on the SI-BONE investor website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
SIBN slipped 0.64% while peers were mixed: TNDM down 3.06%, AVNS down 0.36%, AXGN up 1.97%, OFIX up 0.93%, ZIMV flat. No clear, unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 11 | Q1 2026 earnings | Positive | +19.7% | Revenue grew 11.2% with raised 2026 guidance and stronger profitability metrics. |
| Apr 30 | Conference appearance | Neutral | +6.6% | Announcement of BofA 2026 Healthcare Conference fireside chat and webcast access. |
| Apr 20 | Earnings date notice | Neutral | -3.5% | Set reporting date and call details for Q1 2026 financial results. |
| Feb 23 | FY 2025 earnings | Positive | -2.1% | Record FY 2025 revenue, positive adjusted EBITDA, and 2026 growth guidance. |
| Feb 17 | Conference appearance | Neutral | +3.2% | TD Cowen healthcare conference fireside chat with webcast and 90-day replay. |
Recent earnings beats and guidance raises have often seen positive reactions, while one record-results report drew a mild negative divergence. Non-fundamental conference appearances have generally produced modest, mixed moves.
Over the last few months, SI-BONE reported strong results and guidance, with Q1 2026 revenue of $52.6M and prior FY 2025 revenue of $200.9M, plus raised 2026 guidance. These earnings events on Feb 23 and May 11 showed mixed immediate reactions but underscored improving profitability metrics. Alongside this, the company has repeatedly highlighted its story through major healthcare conferences, similar in nature to the Truist MedTech appearance announced in this article.
Regulatory & Risk Context
An effective S-3ASR shelf filed on Feb 24, 2026 registers an indefinite aggregate amount of securities, including common and preferred stock, debt, and warrants for issuance or resale from time to time. No usage has been recorded yet in the provided context.
Market Pulse Summary
This announcement centers on SI-BONE’s participation in the Truist Securities 2026 MedTech Conference on June 16, 2026, continuing a pattern of high-profile investor outreach. Recent history includes strong earnings, raised 2026 guidance, and an effective S-3ASR shelf filed on Feb 24, 2026. Investors may watch for any new disclosures during the fireside chat, subsequent SEC filings, and how these align with previously raised revenue and margin expectations.
AI-generated analysis. Not financial advice.
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Truist Securities MedTech Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, June 16, 2026, at 5:40 a.m. Pacific Time/ 8:40 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/b4rPMsFmx6FA94q8B8jb82. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing a total of over 150,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 185 peer reviewed publications.
For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.
SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved.
Saqib Iqbal: investors@si-bone.com
